Kornimate/medical-research-clean huggingface dataset:
headache after coil embolization for unruptured intracranial aneurysms

Conditions: Headache; Aneurysm; Endovascular Procedures

Summary: perform a prospective cohort study to compare the incidence and severity of headache between non-stent assisted coiling and stent assisted coiling of unruptured intracranial aneurysms.

severity of headache - assess with visual analogue scale characteristics of headache after stent deployment or simple coiling duration of headache after intervention

Eligibility criteria:
inclusion criteria: * patients with unruptured intracranial aneurysms * patients over 20 years old * patients who can communicate with each other * patients who agreed to this study (with informed consent) exclusion criteria: * patients with recurrent aneurysms after coiling or clipping * patients with allergic reaction to antiplatelets * patients with high risks of hemorrhage * patients with coagulopathy * patients with thrombocytopenia (\<100,000/mm3) * patients with liver disease (\> 100 of aspartate aminotransferase or alanine aminotransferase) * patients with renal disease (\> 2mg/dl of serum creatinine)\\ * patients with uncontrolled heart failure or angina * patients with malignant tumor * pregnant patients * patients with past history that may associated with headache, including subarachnoid hemorrhage, head trauma, intracerebral hemorrhage, trigeminal neuralgia, arteriovenous malformation, brain tumor) * patients who are determined to be disqualified by researchers

Keywords: coil embolization headache stent
comparison of body weight change through different smeglutide administration methods

Conditions: Weight Change, Body

Summary: investigators determined to detect the effect of smeglutide on body weight and metabolic indexes among overweight and obese participants through two different dosing programs.

participants will be randomized into either group. one group will start from 0.25mg per week for four weeks, then increase to 0.5mg per week for four weeks, and 1mg per week maintenance dose for 8 weeks. the other group dosage regime depends on the tolerance of the semaglutide from participants. the dosage will stabilize on the dose how much participant could tolerate. at the end of 16 weeks treatment, comparison will be carried out on weight change before and after treatment and (1) comparison of different administration methods (standards and titrations) on participant compliance, appetite and quality of life improvement; (2) comparison of metabolism (waist hip circumference, body fat and body composition, blood pressure, blood lipid, blood glucose, insulin resistance) in different administration modes; (3) comparison of adverse reactions of metabolic drugs in different administration modes.

Eligibility criteria:
inclusion criteria: 1. 18 ≤ age\<75; 2. overweight or obesity: meet either one of the following standards 1. patients with bmi ≥ 24 kg/m2 and at least one obesity complication (hypertension, hyperlipidemia, apnea syndrome, cardiovascular disease) 2. simple obese patients with bmi ≥ 28kg/m2 3. abdominal obesity, waist circumference ≥ 90 cm for males and ≥ 80 cm for females exclusion criteria: 1. have a personal or family history of medullary thyroid carcinoma (mtc) or have multiple endocrine neoplasia type 2 (men-2) patients. 2. patients with severe hypersensitivity to smeglutide or any other excipient component. 3. diabetic patients (glycosylated hemoglobin ≥ 6.5% or fasting blood glucose ≥ 7.0 mmol/l or blood glucose ≥ 11.1 mmol/l 2 hours after meal or random blood glucose ≥ 11.1 mmol/l). 4. triglyceride\>5.6mmol/l; 5. participants in other clinical drug trials in recent three months. 6. the range of weight change in recent 90 days is\>5kg. 7. cushing's syndrome and abnormal thyroid function. 8. pregnant or breastfed women. 9. the study doctor judged that it was not suitable to participate in the test.
prevention of acute kidney injury initiated with electronic surveillance enhancement

Conditions: Acute Kidney Injury

Summary: introduction: acute kidney injury (aki) increases mortality, hospital cost, and rate of progression toward end stage kidney disease 1-4. early diagnosis and management of aki is known to improve the above mentioned outcomes. hypothesis: the investigators will design and validate an electronic surveillance tool to screen all the icu admissions for the earlier, more efficient diagnosis of aki and as a result improve the outcome of aki in icu patients. methods: the investigators plan to use the patient database, and akin (aki network) definition to design an electronic alert system to allow clinicians discover patients who develop aki. then a randomized clinical trial will be conducted to compare earlier intervention (based on kidney disease: improving global outcomes \[kdigo\] guidelines) initiated by aki sniffer alert to the conventional management provided by primary physician in icu.

a prospective controlled, unblinded clinical trial will be conducted among aki patients who are detected by the use of aki sniffer. the investigators will randomize consecutive patients who were detected to have aki by aki sniffer into two groups. in one group (control group), patients will receive standard clinical care by the primary icu physicians. the primary physicians who take care of the control subjects will be kept blinded of the results of the aki sniffer. all the icu physicians will receive a copy of kdigo (march 2012) guidelines for management of aki prior to the initiation of the patient accrual. in the intervention group, the research team will inform the primary care team about the occurrence of the aki and provides a copy of kdigo guidelines for management of aki to the clinicians. each subject will be followed until hospital discharge or for a maximum of 3 months, for clinical and laboratory data including peak serum creatinine, creatinine at the end of follow up, peak akin stage, along with other secondary outcomes. the investigators will exclude the prevalent cases (aki patients who have had aki documented in their medical records by clinicians prior to the icu admission).

Eligibility criteria:
inclusion criteria: * all patients who are admitted in adult icus in mayo clinic rochester * foley catheter for hourly uop measurement exclusion criteria: * prisoners * patients less than 18 years old. * lack of research authorization (in control group) * esrd on dialysis or s/p kidney transplantation * known aki before admission to icu * moribund patients * prevalent aki admission in icu (patients who have diagnosis of aki documented in their medical records prior to icu admission)

Keywords: acute renal failure acute kidney injury electronic surveillance aki sniffer akin improvement in the process of care and outcomes
sarcopenia and systemic therapy in hcc

Conditions: HCC - Hepatocellular Carcinoma

Summary: this is a multi-center, retrospective observational study in patients with liver cancer (hcc) to assess the impact of sarcopenia (muscle loss) on the prognosis, duration, and tolerance of systemic treatment.

the impact of sarcopenia will be assessed 12 months after the start of chemotherapy. additionally, other factors affecting prognosis will be investigated to develop a specific predictive model for the risk of death at 12 months. finally, an external validation of this predictive model for the risk of death will be carried out.

Eligibility criteria:
inclusion criteria: * patients aged ≥18 years. * diagnosis of hepatocellular carcinoma based on histological and/or radiological results as defined by the european association for the study of the liver (easl) and the american association for the study of liver diseases (aasld). the staging of hepatocellular carcinoma was obtained through contrast-enhanced liver ct and/or mri. * patients with advanced (bclc-c) or intermediate (bclc-b) stage hepatocellular carcinoma, or patients with early-stage (bclc-a) hepatocellular carcinoma who have not responded to previous locoregional ablative treatments and/or liver resection. * treatment with tkis according to the indications and prescription criteria defined by aifa, with no requirement to reach a minimum treatment period. availability of a ct scan performed within no more than 8 weeks prior to the start of tki therapy. - obtaining written informed consent. exclusion criteria: * none

Keywords: hepatocellular carcinoma sarcopenia hcc systemic therapy
supplementary angiographic embolization for peptic ulcer bleeding

Conditions: Peptic Ulcer Hemorrhage

Summary: peptic ulcer bleeding is a common disorder. despite optimal endoscopic and medical treatment, there is a high risk of rebleeding and high mortality. in this study the investigators examine whether combined endoscopic haemostasis and angiographic embolization resolves in a better outcome than the traditional use of endoscopic haemostasis alone. the study is a randomised controlled trail.


Eligibility criteria:
inclusion criteria: * clinical signs of upper gi-bleeding * endoscopic verified high-risk ulcer (forrest i-iib) * primary haemostasis achieved exclusion criteria: * expected lifetime \< 1 month * upper gi-cancer found at endoscopy

Keywords: peptic ulcer hemorrhage peptic ulcer bleeding angiographic embolization arterial embolization angiography
a phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of tak-935 (ov935) as an adjunctive therapy in pediatric participants with developmental and/or epileptic encephalopathies

Conditions: Epilepsy; Dravet Syndrome; Lennox-Gastaut Syndrome

Summary: the purpose of this study is to investigate the effect on the frequency of all seizures (convulsive and drop) in participants treated with tak-935 compared to placebo.

the drug being tested in this study is called tak-935 (ov935). this randomized, double-blind study will assess the effects of tak-935 (ov935), compared to placebo, on efficacy, safety, and tolerability in pediatric participants with dravet syndrome (ds) or lennox gastaut syndrome (lgs). this multi-center trial will be conducted worldwide and will enroll approximately 126 participants. participants will be randomized based on their diagnosis in 2 categories; ds or lgs. the study will consist of 2 periods: screening period and treatment period. the overall duration of treatment period is up to 20 weeks including 8-week dose optimization period and 12-week maintenance period. the overall time to participants in this study is approximately 30 weeks. participants completing this study will have an option to enroll in the open-label extension study, under a separate protocol.

Eligibility criteria:
inclusion criteria: 1. male and female participants aged greater than or equal to (\>=) 2 and less than or equal to (\<=) 17 years 2. clinical diagnosis of ds or lgs 3. weight of \>=10 kilogram (kg) at the screening visit 4. currently taking 1 to 4 anti-epileptic drugs (aeds) at a stable dose 5. failed to become and remain seizure free with trials of at least 2 aeds exclusion criteria: 1. has been admitted to a medical facility and intubated for treatment of status epilepticus 2 or more times in the 3 months immediately prior to the screening visit 2. non-epileptic events that cannot be reliably distinguished from epileptic seizures 3. participation in a clinical study involving another study drug in the previous month

Keywords: drug therapy brain diseases central nervous system diseases tuberous sclerosis cdkl5 deficiency disorder dup15q syndrome anoxic brain injury infantile spams west syndrome cortical dysplasia scn1a ov-935 cholesterol 24s-hydroxylase inhibitor seizure anti-epileptic drug anticonvulsants nervous system diseases drop seizure atonic seizure
retrospective evaluation of liposarcoma

Conditions: Survival , Tumor

Summary: retrospective evaluation of survival after liposarcoma


Eligibility criteria:
inclusion criteria: * patients with liposarcoma treated surgically at our clinic exclusion criteria: * n/a
low level laser intervention for individuals with knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: the purpose of this study was to investigate the intervention effects of low level laser for knee oa group


Eligibility criteria:
inclusion criteria: * the severity of osteoarthritis was defined by the kellgren-lawrence system as grade 2 - grade 3 exclusion criteria: * uncontrolled hypertension * malignant tumor * skin cancer * pregnant * dysesthesia * pacemaker inplement * cognitive problem * fall record within 6 months * dysfunction of blood coagulation
effects of routine physical therapy with and without proprioceptive neuromuscular facilitation on balance, gait and function in patients with parkinson's disease

Conditions: Parkinson Disease

Summary: objective of this study is to compare the effectiveness of routine physical therapy with and without proprioceptive neuromuscular facilitation on balance, gait and function in patients with parkinson's disease. alternate hypothesis: there will be a difference in the effects of routine physical therapy with and without proprioceptive neuromuscular facilitation on balance, gait and function in patients with parkinson's disease. null hypothesis: there will be no difference in the effects of routine physical therapy with and without proprioceptive neuromuscular facilitation on balance, gait and function in patients with parkinson's disease.

it will be a prospectively registered, parallel designed, single blinded randomized controlled trial with concealed allocation, conducted in university of lahore teaching hospital and sir ganga raam hospital, lahore, pakistan. patients who met eligibility criteria will be informed about the aim of study.consent form will be signed by all eligible participants. eligibility of participants will be confirmed by the physiotherapist of research team before randomization. after baseline assessment, eligible patients will be randomly allocated(in a 1:! ratio) in two groups( group a and group b). fish bowl method of randomization will be used and will be done by one of the research team members who will not involve in patient recruitment or assessment or data analysis. randomization assignments will be kept in opaque, sealed envelopes for concealment of group allocation and will be unsealed by researcher after baseline testing. researchers who assess outcomes or will do data analyses will be masked to group allocation.the calculated sample size is 32 (16 in each group), after adding 20% dropout the sample size will be 32+6=38, 19 patients in each group.(statistical power 80% and alpha level of 5%).

Eligibility criteria:
inclusion criteria: * male and female patients of age between 60 and 85 years, diagnosed with parkinson's disease by a neurologist. * patients with hoehn and yahr stages 1-3. * patients with a stable drug program and acclimated to their current medication use for at least 2 weeks. exclusion criteria: * cognitive deficits (scores of \<26 on the mini-mental state examination). * moderate or severe depression (scores of \>17 on the beck depression inventory). * patients with neurological diseases, arthrosis, or total hip joint replacement.

Keywords: parkinson' disease proprioceptive neuromuscular facilitation freezing of gait berg balance scale functional independence measure freezing of gait questionnaire
characterization of obesity-related cardiomyopathy through exploration of human atrial trabeculae contraction

Conditions: Obesity; Heart Failure

Summary: the investigators aim to explore obese cardiomyopathy by studying contractile twitch force, sarcomere sensitivity to calcium and mitochondrial function in atrial myocardial samples of patients grouped according to their body mass index, i.e. normal weight, overweight and obese.

obesity is associated with the development of heart failure, regardless of coronary artery disease or other comorbidities. right atrial samples obtained from patients undergoing cardiac surgery and presenting no sign of clinical cardiomyopathy will be grouped according to patient's body mass index. atrial trabeculae will be explored to dissect out the respective contribution of (i) sarcoplasmic reticulum dysfunction (isometric twitch force contraction analysis), (ii) abnormal sarcomere sensitivity to calcium assessed in permeabilized fibers and (iii) mitochondrial dysfunction to intrinsec contractile dysfunction of myocardium in obese patients.

Eligibility criteria:
inclusion criteria: * patient schedulled for coronary artery bypass graft surgery or aortic valve replacement surgery with extracorporeal circulation * must be over 18 years of age * must be able to read and understand the consent form in french * must be in sinus rhythm at inclusion time exclusion criteria: * medical history of type 1 diabetes * medical history of sustained atrial arrhythmia * pregnancy * class iii anti-arhythmic drug

Keywords: obese cardiomyopathy mitochondria contractile dysfunction
prospective randomized trial evaluating the utility of esophageal stitches during laparoscopic fundoplication

Conditions: Reflux

Summary: this is a prospective trial of the utility of esophageal stitches during fundoplication. the hypothesis is that recurrence rate may be different with or without the esophageal stitches.

this will be a single center, prospective randomized clinical trial involving patients who require an operation for gastroesophageal reflux disease. this is intended to be a definitive study. all patients will receive the standard operation for reflux: laparoscopic fundoplication. the dissection will be performed by leaving the phrenoesophageal membrane intact in all patients. one group will undergo laparoscopic fundoplication with 4 esophageal-crural sutures while the other group will not have these placed. the operation, post-operative care, and follow-up plan will otherwise not differ between groups.

Eligibility criteria:
inclusion criteria: patients less than 7 years of age requiring fundoplication for gastroesophageal reflux disease who are considered good laparoscopic candidates by the staff surgeon will be considered candidates. exclusion criteria: 1. hiatal hernia demonstrated on preoperative contrast study, computed tomography, endoscopy, or intraoperative findings. 2. prior esophageal operation (e.g. esophageal atresia repair, esophageal myotomy) 3. prior operation for congenital diaphragmatic hernia 4. patients not considered laparoscopic candidates by the staff surgeon or anesthesiologist (e.g. carbon dioxide retaining lung disease, congenital heart disease, or complex previous abdominal operations)

Keywords: fundoplication gastric reflux
treatment of cerebral arteriovenous malformations with squid liquid embolic agent (choice)

Conditions: Cerebral Arteriovenous Malformation

Summary: the objective of this study is to further establish that squid, an alternative liquid embolic agent with specific properties, is a safe and effective alternative in bavm endovascular treatment strategy available to date. therefore, the performance of squid will be documented and its safety of use will be confirmed in current practice.


Eligibility criteria:
inclusion criteria: * patient planned for one or multiple embolization sessions using squid to achieve occlusion of a previously untreated bavm.\* \*patients with a direct fistula or saccular/flow-related aneurysm previously treated with nbca and/or coils may be included. * patient in whom the use of squid had been decided for an embolization alone or in association to neurosurgery or radiotherapy. * patient ≥18 years old. * patient or authorized representative dully informed and having no objection to the clinical data collection and medical file access. an informed consent form must be signed and dated whenever required by local legislation exclusion criteria: * patient with bavm not eligible for endovascular treatment. * patient with bavm previously treated by embolization with other devices (liquid embolic agent, nbca, particles, and coils).\* \*patients with a direct fistula or saccular / flow-related aneurysm previously treated with nbca and/or coils may be included. * patient with bavm previously treated with surgery or radiotherapy. * patient intended to undergo surgery and embolization during the same procedure at first embolization * patient with multiple bavm or bavm associated with dural arteriovenous fistula\*. \*patients with a direct fistula or saccular / flow-related aneurysm previously treated with nbca and/or coils may be included. * patient presenting contra-indication to the use of squid according to the instructions for use. * intention to treat with any non-adhesive embolic liquid other than squid, or planned treatment with another non-adhesive embolic liquid over the course of the endovascular treatment phase. * patient planned for a total endovascular treatment phase duration exceeding 2 years. * patient participating in another clinical study evaluating another medical device, another procedure or a medication. * any condition or any situation that would prohibit the patient from coming to the investigational center for the follow-up as recommended by the study protocol between 3 and 6 months, or prohibit carrying out the telephone mrs assessments at 1 month after each embolization session and at 12 months after the end of the endovascular treatment phase.
trampoline exercises children with developmental coordination disorder

Conditions: Developmental Coordination Disorder

Summary: rct in which 28 children with developmental coordination disorder (dcd) were enrolled and equally distributed into two groups; participants in control group were treated with conventional physical therapy while experimental were given conventional physical therapy in addition to trampoline exercises. assessment was at 0, 4 and 8 week using developmental coordination disorder questionnaire (dcdq), pediatric balance scale (pbs) and peads quality of life (pql)


Eligibility criteria:
inclusion criteria: * children with dcd indicated using dcdq. exclusion criteria: * no developmental coordination disorder * declined to participate * progressive unstable health condition.

Keywords: balance developmental coordination disorder motor activity quality of life
cryosurgery in treating women with breast lesions

Conditions: Breast Cancer

Summary: rationale: cryosurgery kills cancer cells by freezing them. cryosurgery followed by lumpectomy or mastectomy may be an effective treatment for breast lesions. purpose: phase i trial to study the effectiveness of cryosurgery in treating women who have breast lesions.

objectives: * determine the feasibility of temperature-monitored, ultrasound-guided cryosurgery in women with highly suspicious breast lesions. * determine the safety of this procedure in these patients. outline: this is a multicenter study. patients undergo cryoablation of up to two breast lesions. within 3-21 days, patients undergo lumpectomy or mastectomy. patients are followed at 1, 4, 8, and 12 weeks after lumpectomy or mastectomy. projected accrual: a maximum of 25 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * highly suspicious breast lesion on prior mammogram and/or ultrasound with confirmation of malignancy on ultrasound-guided core biopsy * tumor no greater than 2.0 cm in diameter * eligible for lumpectomy or mastectomy * no superficial breast lesions * no prior open surgical biopsy * hormone receptor status: * not specified patient characteristics: age: * any age sex: * female menopausal status: * not specified performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * not specified renal: * not specified other: * no other illness that would preclude study participation prior concurrent therapy: biologic therapy: * not specified chemotherapy: * not specified endocrine therapy: * not specified radiotherapy: * not specified surgery: * see disease characteristics * no other surgery that would preclude study participation other: * no other medical treatment that would preclude study participation

Keywords: stage i breast cancer stage ii breast cancer